10 Nicotinamide adenosine dinucleotide (NAD) has been found to be covalently attached to the 5'-11
nicotinamide moiety of NAD and the nucleotides at the -1 position of the DNA non-coding strand 80
(thymidine (T) and cytidine (C)) (Vvedenskaya et al., 2018) . 81
The functions of the NAD cap are not yet fully understood, but in prokaryotes, it seems to confer 82 stability to RNA. In E. coli, the NAD cap protects RNA against 5′-processing by the RNA-83 pyrophosphohydrolase (RppH) and thereby against RNaseE degradation (Cahová et al., 2015) , 84
whereas in B. subtilis, it stabilises RNA against exoribonucleolytic attack by RNase J1 (Frindert et 85 al., 2018) . Furthermore, E. coli possesses an NAD-decapping machinery based on the Nudix 86 phosphohydrolase NudC (Frick & Bessman, 1995) , which efficiently hydrolyses the NAD cap and 87 leaves a 5'-monophosphate RNA (p-RNA) (Cahová et al., 2015) . Despite Nudix hydrolase motifs 88 being present in several enzymes of S. aureus, no NudC ortholog has been found to date. In 89 mammalian cells, the NAD-decapping machinery works in a very different way. The DXO enzymes 90
first remove the entire NAD cap from an mRNA (releasing NAD and p-RNA) and then proceed 91
with exonucleolytic mRNA decay (Jiao et al., 2017) . 92
In this study, we reveal by NAD captureSeq the presence of NAD-capped mRNAs and regulatory 93
RNAs in the opportunistic pathogen S. aureus. The highly expressed, multifunctional, protein-94 coding, and regulatory RNA, RNAIII, is found to bear the NAD cap. Additionally, we study the 95 importance of the -1 and +1 positions of the P3 promoter for the incorporation of NAD into RNAIII 96 in vivo. Finally, we also investigate the consequences of changing RNAIII's NAD modification ratio 97 on S. aureus virulence. The obtained results are interpreted in the context of the current 98 knowledge of S. aureus's pathobiology. 99 4
Results 100
S. aureus possesses NAD-capped RNAs. 101
To detect and quantify NAD-capped RNAs in S. aureus, Liquid Chromatography coupled with Mass 102
Spectrometry (LC-MS) analysis of total RNA samples was carried out. Two RNA samples from S. 103 aureus ATCC 25923 were washed extensively to remove contaminating free NAD before 104 enzymatic treatment with E. coli NudC and alkaline phosphatase. Upon this treatment, NAD-RNAs 105 will liberate N-ribosylnicotinamide (r-NA) that can be sensitively detected by MS analysis. The 106 results revealed an average amount of 25.25 ± 1.64 fmol of NAD-RNA per microgram of RNA, 107 which corresponds to an estimated amount of 897 ± 58 NAD-RNA molecues per cell (Table S1 ) 108
(Chen, Kowtoniuk, Agarwal, Shen, & Liu, 2009). These results indicated the presence of NAD-109
capped RNAs in S. aureus. 110
In order to identify NAD-capped RNAs, NAD captureSeq was performed (Winz et al., 2017 ) Total 111
RNA from S. aureus ATCC 25923 (isolated at the late exponential phase) was treated per duplicate 112 either with ADP-ribosyl cyclase (ADPRC), allowing selective biotinylation of NAD-RNA, or mock-113 treated (minus ADPRC control). The captured RNAs were reverse transcribed and PCR-amplified 114
to generate a DNA library for Illumina sequencing ( Figure S1A ). The distribution of the obtained 115 normalised mapped reads revealed 96.87% mRNAs, 2.46% tRNAs, and 0.68% rRNAs with 116 enrichment values up to 50-fold. Enriched hits (P < 0.05, log2-fold change > 2, base mean > 10) 117
were visualised with the Integrated Genome Browser (Nicol, Helt, Blanchard, Raja, & Loraine, 118 2009) to identify reads that clustered at the 5'-ends of transcripts initiating with adenosine (+1A) 119
( Figure 1B) . 67.7% of the initial enriched hits (21 out of 31) had these properties (Table S2 ) and 120 are indicated as green dots in the upper right sector of the scatter plot ( Figure 1B) . The TSS 121 analysis of the enriched hits showed T (61.9%) or A (28.6%) at position -1 of the promoter 122
predominantly. G or T usually occupy the +2 position with the same occurrence (33.3%) whereas 123 +3 position is dominated by A (57.1%). The predominant nucleobase at position -3 and -2 of the 124 promoter was A (71.4% and 47.6% respectively, Figure S1B ). Most enriched RNAs turned out to 125 be mRNA 5'-fragments (Table S2 ). However, the most abundant and the most enriched hit was 126 the bifunctional RNAIII (hld/RNAIII gene, Figure 1B , green star). Notably, the other transcript from 127 the agr locus, RNAII, which has a similar promoter and is reported to also initiate with A (Novick 128 et al., 1995; Reynolds & Wigneshweraraj, 2011), was not enriched at all ( Figure 1B, red star) . 129
The multifaceted regulatory RNAIII contains a 5'-NAD cap. 130
The obtained reads for hld/RNAIII gene mapped clearly on its 5'-UTR ( Figure 1C ). As NAD 131 captureSeq does not use a fragmentation step and size-selects (at the very end, after PCR 132 amplification) amplicons that correspond to RNAs < ~170 nt, information about full-length mRNA 133 species cannot be obtained from these data. To quantitatively investigate the length distribution 134
of NAD-RNAIII, qPCR was performed on the enriched cDNA obtained directly from reverse 135 transcription, before any amplification or size fractionation using gene-specific primers (Table S3 ) 136
targeting different regions of RNAIII, thereby comparing the cDNA from the NAD captureSeq 137 sample with the mock-treated negative control. The qPCR data revealed the most substantial 138 enrichment for the 5'-end region, but a significant presence and enrichment of full-length RNAIII 139
( Figure 1D ). Northern blot analysis (which is independent of the nature of the 5'-end) indicated 140 that overall, RNAIII in S. aureus is predominantly full-length ( Figure S1C ). 141
To confirm that the NAD is covalently linked to RNAIII's 5'-end, RNAIII (enriched) and 5SrRNA 142
(non-enriched, negative control) were specifically isolated from S. aureus total RNA by pull-down 143 using biotinylated complementary oligonucleotides. Afterwards, RNAs were quantified, treated 144
with NudC and alkaline phosphatase, and the small-molecule fraction analysed by LC-MS ( Figure  145 1E). This analysis revealed an intensive peak corresponding to nicotinamide (m/z = 122.81, 146 originating from r-NA, m/z = 254.94) in the case of RNAIII, whereas for 5SRNA the same peak 147 could only be detected at 24-fold higher input RNA concentration ( Figure 1F ). The NAD 148 modification ratio, i.e., the percentage of molecules of that RNA species that carry the 5'-NAD-149 modification, of RNAIII and 5SrRNA was calculated as 36.20% and 0.25%, respectively ( Figure 1F ). 150
Guanosine at position -1 of the P3 promoter increases NAD incorporation into RNAIII in 151 vivo. 152
To investigate the biological consequences of 5'-NAD modification in vivo, S. aureus strains that 153 differ strongly in their content of 5'-NAD-RNAIII, with as little as possible differences in the 154 transcriptome, had to be generated. Toward this end, we complemented a strain devoid of the 155 hld/RNAIII gene (S. aureus HG001 ΔRNAIII) with plasmids based on the shuttle vector pCG-246 156 (Helle et al., 2011) . These plasmids carried the hld/RNAIII gene behind different promoters: pCG-157
P3 carried the native P3 promotor, while pCG-P3(-1G) had a mutated version of this promoter (-158 1T to -1G). To unravel whether the lack of NAD captureSeq enrichment of RNAII was due to 159
properties of its promoter, construct pCG-P2 was generated in which the P2 promoter controlled 160 the RNAIII native sequence (Figure 2A ). Unlike the previously used S. aureus ATCC 25923, in the 161 generated strains the hld/RNAIII gene is located on a plasmid. 162
To detect variations in RNAIII's modification ratio, we analysed RNAIII pulled down from total 163
RNA from the RNAIII-complemented S. aureus strains by acryloaminophenyl boronic acid (APB) 164 gel electrophoresis that separates 5'-NAD-RNA from 5'-p and 5'-ppp-RNA, combined with 165
Northern blot (Alwine, Kemp, & Stark, 1977; Igloi & Kossel, 1985 ; Nübel, Sorgenfrei, & Jäschke, 166 2017). As the full-length RNAIII was too long for efficient separation and precise quantification 167 ( Figure S1D ), a pre-treatment with a designed DNAzyme was introduced which cleaved RNAIII to 168 yield 125 nt 5'-terminal fragments ( Figure 2B ). The strains containing pCG-P2 showed no NAD 169 incorporation into the RNAIII transcript at all, whereas RNAIII in pCG-P3 and pCG-P3(-1G)-170
transformed strains showed an average NAD-modification ratio of 9.82± 0.15% and 24.91 ± 171 0.37%, respectively ( Figure 2C ). Indeed, S. aureus pCG-P(-1G) was found to have a significantly 172
higher amount of NAD-RNAIII than S. aureus pCG-P3 (t-test; P < 0.0001), demonstrating the 173 importance of the -1 mutation on NAD incorporation efficiency, which confirms findings in other 174 microorganisms Vvedenskaya et al., 2018) . In all RNAIII samples, the slower-175 migrating band disappeared upon treatment with E. coli NudC, further supporting the nature of 176
the 5'-modification as NAD ( Figure 2C ).
177
To test whether this different NAD modification percentage in the three RNAIII constructs (pCG-178 P3, pCG-P2, pCG-P3(-1G)) is also reflected in NAD captureSeq enrichment, we had to modify the 179 analysis to allow quantitative comparisons between different RNA species by adding pure NAD-180
RNA spike-in controls of five different lengths as internal standards (IS; 61, 104, 205, 302 and 400 181 nt, Table S4 ) to allow for normalization. The NGS results revealed that the NAD capture efficiency 182 of the IS between the samples was very similar ( Figure 2D , one-way ANOVA; P = 0.8617). When 183 comparing the hld/RNAIII enrichment in the different S. aureus strains, pCG-P3(-1G) 184
(log2FoldChange = 3.57) showed higher enrichment than S. aureus pCG-P3 (log2FoldChange = 185 2.77). In the case of S. aureus pCG-P2, no enrichment was found for hld/RNAIII (log2FoldChange 186 = 0.48). Thus, the NGS data support the results obtained by APBgel -Northern blot analysis and 187
confirm that a -1G in the P3 promoter significantly enhances NAD incorporation into RNAIII (t-188 test; P = 0.036, Figure 2E ). Analysis of the NAD captureSeq data from the three mutant strains 189 revealed a similar pattern of NADylation as in the ATCC 25923 wild type strain (Table S5 , Table  190 S6 and Table S7 ). For pCG-P3 we obtained 11 enriched hits (4 of them common with the wild 191 type), in pCG-P3(-1G) 12 (4 commons), and pCG-P2 6 (3 commons). 192
The TSS of the P2 promoter is guanosine. 193
We were puzzled by the observation that RNAIII from strain pCG-P2 seemed to contain no NAD 194 at all. Sanger sequencing data after cRT-PCR ( promoter, and +1G in the case of the P2 promoter ( Figure 2F ). A +1G was also found in RNAII (a 201 natural product of P2 promoter) from S. aureus HG001 wild type strain after the analysis of 10 202
Sanger sequencing reactions (10 single colonies, Figure 2F ). 203
The 5'-NAD cap of RNAIII affects Hla and Hld expression levels and thereby S. aureus's 204 cytotoxicity. 205
To study the accessibility of its NAD-5'-end, 32 P-body-labelled pure NAD-RNAIII was subjected to 206 in vitro cleavage with E. coli NudC. After 20 min of incubation at 37 °C, NudC had decapped ~65% 207 of the RNAs, and this value did not change upon further incubation (up to 1 hour, Figure 3A ). An 208 additional unfolding-folding cycle, followed by the addition of fresh NudC, increased decapping 209 to ~83% ( Figure 3A ), suggesting that a fraction of NAD-RNAIII exists in a structure that is not 210 susceptible to NudC cleavage, e.g., with the 5'-end involved in a double-strand (Höfer, Abele, 211
Schlotthauer, & Jäschke, 2016).
212
To test the effect of the promoter mutations on the biosynthesis rate of RNAIII, a qPCR assay was 213 performed with cDNA from the different S. aureus strains (total RNA harvested in late 214 exponential phase and reverse transcribed). The assay revealed no significant difference in RNAIII 215 content between pCG-P3 and pCG-P3(-1G) strains (t-test; P = 0.1221, Figure 3B ). On the other 216
hand, pCG-P2 showed a significantly lower amount of RNAIII than pCG-P3 (t-test; P = 0.0276, 217 Figure 3B ). 218
Strains pCG-P3 and P3(-1G) differ only in one nucleotide, the -1 position of the P3 promoter, 219
which leads to the same RNAIII transcript, just with different NAD modification levels. To test the 220 influence of this single mutation on the transcriptome; RNA-Seq was performed on total RNA 221 from both strains. Their transcriptomes were found to be very similar to each other, with only 4 222 upregulated genes (splA, splB, splC, splD, all of them coding for serine proteases, Table S8 ) and 2 223 downregulated genes (spa, an uncharacterized gene with homology to ssaA, Table S8 ) in S. 224
aureus pCG-P3(-1G). The splABCD operon is known to be activated via RNAIII, whereas spa is 225 known to be inhibited by RNAIII (Queck et al., 2008) . Thus, the higher NADylation in pCG-P3(-1G) 226 might enhance RNAIII's inhibitory activity. Interestingly, the prototypic RNAIII target gene, hla, 227
was neither upregulated nor downregulated in the RNA-Seq data. Hence, we speculated that 228
NADylation of RNAIII may influence the translation of Hla, and therefore, an analysis of Hla 229 abundance in culture supernatants was conducted. The Hla obtained in culture filtrates of S. 230
aureus pCG-P3(-1G) was significantly lower than in S. aureus pCG-P3 in late exponential phase 231
cultures (t-test; P = 0.0148, Figure 3C and Figure S1E ). Thus, 5'-NAD capping of RNAIII might 232 modulate the interaction between the 5'-UTRs of RNAIII and hla mRNA as well, leading to a lower 233 translation of the latter RNA. 234
We next analysed whether NADylation impacts the translation efficiency of the RNAIII-encoded 235
Hld. According to LC-MS of culture filtrates, half the amount of Hld was found in pCG-P3(-1G) 236
(with the higher amount of 5'-NAD cap) compared to pCG-P3 ( Figure 3C , Figure S1F ). This finding 237
indicates that RNAIII's 5'-NAD cap might impair hld mRNA translation. A decreased production of 238 two major hemolytic toxins, Hla and Hld, should lead to a less cytotoxic S. aureus strain. Indeed, 239
an assay with S. aureus pCG-P3 and pCG-P3(-1G) culture supernatants in a human THP1 240 macrophage line ( Figure 3D ) revealed a significantly reduced cytotoxicity of pCG-P3(-1G) 241 compared to pCG-P3 (Tukey's multiple comparisons-test; P = 0.0004). 242
Hld's Shine-Dalgarno sequence is accessible in vitro regardless of the presence of a 5'-243 NAD cap. 244
In order to analyse whether 5'-NAD capping of RNAIII affects the secondary structure of its 5'-245 domain, we performed Selective 2'-Hydroxyl Acylation and Primer Extension (SHAPE) (Weeks & 246 Mauger, 2011; Wilkinson, Merino, & Weeks, 2006) . SHAPE is an approach to probe the structure 247 of every nucleotide within an RNA simultaneously. The SHAPE reagent chemically modifies To determine whether RNAIII's secondary structure is modulated by 253 the nature of its 5'-end, pure 5'-NAD-RNAIII and ppp-RNAIII were required. Pure full-length (514 254 nt) NAD-RNAIII could not be prepared, as no method exists for its preparative separation from 255
full-length ppp-RNAIII. Therefore, we first probed a shorter version of RNAIII consisting of 256 nucleotides 1 to 113, designated as RNAIII leader, which could be prepared by in vitro 257 transcription and APB-gel purification as pure NAD-capped (NAD-RNAIII leader), or pure 258 triphosphorylated version (ppp-RNAIII leader). To exclude the possibility that the truncated 259
RNAIII leader sequences fold differently than the full-length RNAIII, we compared in a second 260 step pure full-length ppp-RNAIII with impure full-length NAD-RNA (containing NAD-RNA and ppp-261 RNA ~ 1:1). The SHAPE data showed very similar nucleotide reactivity profiles for NAD-RNAIII 262 leader and ppp-RNAIII leader ( Figure 4A , Figure 4B and Figure S1G ), indicating an accessible SD 263 sequence regardless of their 5'-end modification. 264
When shaping full-length ppp-RNAIII and the ppp-/NAD-RNAIII mixture, both the overall SHAPE 265 reactivity profile and SD's accessibility were similar to that of the ppp-RNAIII leader ( Figure 4C , 266 Figure 4D ) 267 5 Discussion 268
A short, regulatory, and protein-coding NAD-capped RNA in S. aureus. 269
In this study, we have demonstrated the existence of 5'-NAD-capped RNAs in the opportunistic 270 pathogen S. aureus. Since the discovery of the prokaryotic NAD cap in 2015, the presence of NAD-271
RNAs in many different organisms has been confirmed, and this modification might be 272
ubiquitous. Nevertheless, the biological function of the 5'-NAD cap in prokaryotes is still unclear. 273
In the case of B. subtilis, also a gram-positive bacterium, the NAD cap stabilises RNA against 274 exoribonucleolytic attack by RNase J1 in vitro . As in other organisms 275 (Cahová et al., 2015; Frindert et al., 2018) , several mRNAs were found to be enriched in the NAD 276 captureSeq of S. aureus ATCC 25923. Most of these mRNAs encode proteins involved in different 277 cellular processes: redox reactions, membrane transport, biosynthesis-related enzymes, 278 phosphatases, kinases, and hydrolases (Table S2) . Similar classes were observed in the S. aureus 279 mutant strains (pCG-P3, pCG-P3(-1G) and pCG-P2), with several hits common with the wild type 280 ATCC 25923 strain, i.e., NADP reductases, synthetases, and transcription factors. 281
Interestingly, the mutant-specific hits encoded for proteins that were similar to the ones found 282
in the wild type strain, especially reductases such as the peptide methionine sulfoxide reductase 283 or redox enzymes like the superoxide dismutase (Table S5, Table S6 and Table S7 ). Of particular 284
interest is the enrichment of mRNAs that encode for NAD-NADP-utilizing enzymes (2-285 dehydropantoate 2-reductase, L-lactate dehydrogenase). A similar observation has been made 286 in B. subtilis, where L-threonine 3-dehydrogenase (tdh) was enriched . These 287
findings underpin the possibility that some NAD-mRNAs might act as a cofactor of their encoded 288 enzyme. Moreover, the NAD cap could act as an enzyme-binding site to its mRNA as an additional 289 regulatory mechanism (Jaschke, Hofer, Nubel, & Frindert, 2016). However, the existence of this 290 feedback mechanism still needs to be demonstrated empirically.
291
The hld/RNAIII gene was by far the most enriched of all hits. The results showed a higher NAD 292 modification level of RNAIII in the wild type strain (~36%) compared to pCG-P3 (~10%). This 293 phenomenon might be due to the different S. aureus strains used (ATCC 25923 and plasmid-294 carrying HG001) although these values were obtained by different approaches (LC-MS vs 295
Northern blot). The variation in NAD content is supported by a different hld/RNAIII enrichment 296
in NAD captureSeq between both strains after, with a higher value obtained in ATCC 25923 (Table  297 S2, Table S5 ). Furthermore, a distinct NAD modification level on RNAIII could be the cause of 298 some differences in the infective behaviour between the strains. Nevertheless, RNAIII is still 299 strongly NAD-modified whenever transcribed by P3 promoter, and this together with its high 300 expression level, its role as a crucial intracellular effector of the quorum-sensing system, and the 301 additional presence of an embedded ORF for the hld gene ( Figure 1A ) make RNAIII a promising 302 candidate for unveiling a biological function of the NAD cap. 303
The P3 promoter acts as a driver of NAD incorporation. 304
The -1 position of the P3 promoter is found to modulate the incorporation of NAD into the 305
nascent RNAIII. We also tested the effect of a promoter exchange on NAD transcriptional 306 incorporation. The other promoter of the agr locus, P2, seems not to be prone to introduce NAD 307
into RNAII (Log2FC = -1.65 in NAD captureSeq). These two promoters share several 308 characteristics: phosphorylated AgrA activates transcription of both, they have a suboptimal 309
interspace region between the -35 and -10 boxes, and both have been predicted to initiate with 310 a +1A (Novick et al., 1995; Reynolds & Wigneshweraraj, 2011) . Placing the P2 promoter upstream 311 of the RNAIII sequence led to the total abolishment of NAD incorporation into RNAIII ( Figure 2C  312 and Figure 2E ). The unexpected revelation of the TSS of the P2 promoter being G instead of A 313
( Figure 2E ) provided us with an additional "NAD zero" control in our experiments, constituting a 314
transcript that differed only in one nucleotide from the native one but was devoid of any 5'-NAD.
315
This control further demonstrated that NAD captureSeq is not biased towards highly expressed 316
RNAs unless they bear the NAD cap. Moreover, it also confirmed the reliability of the APBgel-317
Northern blot combination as a tool for analysing NAD-capped RNAs. 318
NAD-RNAIII as a modulator of S. aureus physiology. 319
For validating the function of RNAIII's NAD cap, it was essential that the RNAIII expression of the 320 different S. aureus strains was not altered by the changes introduced in the promoter sequence. 321 qPCR analysis confirmed the lack of bias in RNAIII content between S. aureus pCG-P3 and pCG-322 P3(-1G) ( Figure 3B ). This experiment also showed lower RNAIII levels in the pCG-P2 strain ( Figure  323 3B), which suggest that the P2 promoter is less active than the P3 promoter in these experiments. 324
This finding is in agreement with the fact that in vitro, AgrA-mediated activation of transcription 325 is more prominent at P3 than at P2 (Reynolds & Wigneshweraraj, 2011) . On the other hand, a 326 recent in vivo study reported AgrA~P affinity to P2 to be higher than to P3, previously assessed 327
by Koenig et al. (2004) , and this differential affinity being crucial for the agr positive feedback 328 loop (Garcia-Betancur et al., 2017).
329
According to transcriptome sequencing, the higher NAD modification ratio of RNAIII in S. aureus 330 pCG-P3(-1G) ( Figure 2C and Figure 2E ) appears to downregulate the transcription of spa (protein 331 A) and ssaA (staphylococcal secretory antigen SsaA) (Table S6) the vicinity of helix 13. Hence, it is conceivable that the 5'-NAD cap affects the folding of RNAIII 339
and its interaction with the spa mRNA. A stronger interaction might lead to a decreased protein 340
A production, which would ultimately favour the dissemination of S. aureus pCG-P3(-1G) isolates 341
(Bronesky et al., 2016). Furthermore, four genes for a protease family occurring only in S. aureus, 342
(SplA/B/C/D operon) (Reed et al., 2001) were upregulated in the strain with increased NAD-343
RNAIII. Also, the Spl operon is induced by the agr-system with a mechanism that has not been 344 elucidated but that might involve RNAIII (Reed et al., 2001) . The Spl proteases have been 345 implicated in tissue dissemination processes due to their ability to degrade host proteins (Paharik 346 et al., 2016) . Noteworthy, a recent study reported a decrease in the amount of Hld in the spent 347 medium obtained from an S. aureus Spl deletion mutant, suggesting a positive correlation 348 between RNAIII and SpI. On the other hand, the ΔSpl strain did not show alterations in Hla levels, 349
proving that the agr system was not inhibited (Paharik et al., 2016) .
350
At this point, one could expect that the upregulation in Spl proteases in pCG-P3(-1G) together 351
with the downregulation of protein A and SsaA would generate a more invasive bacterium than 352 pCG-P3. Nevertheless, evidence at protein level of these two targets would be necessary to 353 predict more accurately the phenotypic effects.
354
Transcriptome sequencing did not reveal significant changes in another major target of RNAIII, 355
namely hla (Log2FC = -0.14). However, as RNAIII activates translation of hla mRNA by base pairing 356 between the 5'-UTRs of both RNAs (Morfeldt et al., 1995) , an effect on the mRNA level of this 357 gene was not expected.
358
On the protein level, the phenotypic effects were more notorious. Since pCG-P3(-1G) exhibits an 359
upregulated Spl operon, an increase in Hld amount in supernatant could be expected. In contrast, 360 a significant decrease of Hld in cell culture filtrates of S. aureus pCG-P3(-1G) was observed ( Figure  361 3C). 362
One explanation would be that the 5'-NAD cap in RNAIII might impair Hld translation. In Hence, it appears plausible that the 5'-NAD cap of an 372
RNA interacts similarly with C and uridine (U) residues inside the same molecule. Nevertheless, 373
even if one assumes that NAD-RNA is not translated while ppp-RNA is, this could not explain how 374 a 15% reduction in ppp-RNAIII in pCG-P3(-1G) compared to pCG-P3 ( Figure 2C ) can cause a 50% 375 decrease in translation product yield. We assume that this effect may be due to yet unknown 376 factors that modulate hld translation. 377
In the case of Hla, the changes observed in pCG-P3(-1G) compared to pCG-P3 are slightly lower 378 than for Hld ( Figure 3C ), which might imply a lower influence of the 5'-NAD-cap on the RNAIII-hla 379 mRNA interaction than on RNAIII translation. Indeed, the fact that the H2 hairpin of RNAIII, which 380
is the one predicted to interact with hla mRNA, is only nine nucleotides upstream of hld's SD 381 sequence suggests that both might be similarly affected by the 5'-NAD cap. Like in the case of 382
Hld translation, nicotinamide's base-pairing flexibility might increase the probability of 383 generating a 5'-end-3'-UTR duplex in RNAIII's secondary structure, sequestering both the SD 384 sequence and H2 helix, and explaining the phenotypes obtained in S. aureus pCG-P3(-1G) ( Figure  385 3C and Figure 3D) . Surprisingly, the in vitro analysis of RNAIII leader's secondary structure by 386 SHAPE did not reveal differences related to the 5'-NAD cap ( Figure 4A ). In both RNAIII leader 387 variants, the SD appeared to be accessible ( Figure 4B ). This structure would likely be compatible 388
with translation of the embedded Hld ORF regardless of the presence of the 5'-NAD cap. Of note, 389
the analysis was done with a shortened version of RNAIII with the aim of detecting the presence 390 of a mechanism that would block co-transcriptional translation. Furthermore, SHAPE 391 measurements with full-length RNAIII revealed an accessible SD sequence as well ( Figure 4B , 392 Figure 4C , Figure 4D ), an observation already reported in the chemical probing of RNAIII 393
performed by Benito et al. (2000) . Our data suggest that the lack of RNAIII's 3'-domain would not 394 exert any effect on Hld and Hla translation ( Figure 4B , Figure S1G ). In contrast, a mutant S. aureus 395 strain with a truncated RNAIII devoid of its 3'-end domain (211 nt) showed an earlier Hld 396 translation compared to the wild type strain (Balaban & Novick, 1995) . Likewise, deletions within 397
3'-end region of RNAIII also inhibit Hla expression (Novick et al., 1993) . Thus, although the in vitro 398
RNAIII SHAPE experiments do not explain the obtained phenotypes with decreased Hld and Hla, 399
in a regulated cellular co-transcriptional translation environment, the 5'-NAD cap could cause 400 some differences and, induce different phenotypes. 401
While RNAIII has been studied intensively as a central regulator of bacterial physiology, a large 402 number of different targets affected by it, and the diversity of mechanisms of action make it 403
rather unlikely that only one stable secondary structure induces all these responses. Instead, 404
inside the cell likely exists an equilibrium between different folds, each of them suited for specific 405
purposes (Benito et al., 2000) . The existence of such alternative folds has been hinted at by the 406 inaccessibility of a fraction of in vitro-transcribed NAD-RNAIII to NudC cleavage, and its 407 modulation by an unfolding / folding cycle ( Figure 3A) . Thus, the existence in the cell of an RNAIII 408 subpopulation that is sensitive to its 5'-modification state and is responsible for both hld and hla 409 activation remains plausible (Balaban & Novick, 1995) . 410
The fact that the RNAIII sequence is highly conserved among S. aureus strains led us to 411
hypothesize that the incorporation of NAD into RNAIII should be strictly regulated and therefore 412 the evolution selected the -1T at P3 promoter. In such a way, S. aureus may ensure the right 413
(intermediate) level of NAD incorporation into RNAIII and preserves its optimal ensemble of 414 secondary structures. Assuming this, the 5'-NAD cap might serve as modulator of RNAIII's 415 secondary structure. Moreover, the NADylation of RNAIII is likely dependent on the bacterial 416 redox state and might be a new mechanism to fine-tune agr activity. 417
Outlook. 418
In this study, we have discovered another prokaryotic organism that possesses NAD-capped 419
RNAs. However, it constitutes the first evidence of this phenomenon in pathogenic bacteria to 420 date. More importantly, we have found that a crucial regulatory and protein-coding RNA (RNAIII) 421
is strongly NAD-modified and that alterations on its NAD-modification state lead to significant 422 effects that modulate S. aureus's cytotoxicity that could be related to an alternative secondary 423 structure of RNAIII. However, and despite these exciting findings, the role of 5'-NAD-RNAIII 424 remains unclear. Further studies will be conducted to unravel how exactly the NAD cap changes 425
RNAIII's secondary structure and how this change contributes to the overall secondary structure 426 ensemble of RNAIII. Furthermore, in vivo studies applying our mutant S. aureus strains to animal 427
infection models are planned to study the pathogenicity of this bacterium. the constructs were introduced into S. aureus ΔRNAIII Δpsmαβ. Genomic DNA from S. aureus 437
ATCC 25923 was used to amplify the P3 promoter, P2 promoter, and RNAIII sequences (Q5 Hot 438
Start High-Fidelity DNA Polymerase, NEB). The bacterial strains used in this study are summarised 439
in Table S9 . 440
Generation of constructs. 441
The RNAIII sequence with the native P3 promoter sequence upstream was amplified from 442
Genomic DNA from S. aureus ATCC 25923. The PCR amplification was carried out with the primers 443
Fwd-P3-RNAIII/Rv-P3-RNAIII; as a consequence, the restriction sites BamHI and EcoRI were 444
introduced in the amplicon. The P2 promoter sequence was fused to RNAIII by the following 445 procedure: a PCR with the primers Fwd-P2/Rv-P2hyb was performed in order to generate a P2-446 amplicon with a 20 bp overhang on its 3'-end which was complementary to RNAIII's first 20 nt. 447
The PCR with primers Fwd-RNAIII/Rv-RNAIII originated a second amplicon containing the whole 448 RNAIII sequence. Both amplicons were used as primers and subjected to PCR in order to generate 449 the P2-RNAIII product, which contained BamHI and EcoRI restriction sites. Both PCR products 450 were treated with BamHI and EcoRI and cloned into the pCG-246 shuttle vector (Helle et al., 2011) 451 yielding the constructs pCG-671 and pCG-672. The RNAIII terminator sequence was introduced 452 afterwards in both of the constructs by site-directed mutagenesis generating pCG-P3 and pCG-453 P2 plasmids. Besides, a mutation at the -1 position (-1T to -1G) respect to the TSS of the P3 454 promoter was inserted by site-directed mutagenesis, yielding plasmid pCG-P3(-1G). All primers 455 used are summarised in Table S3 . 456
NAD captureSeq and RNA-seq Next Generation Sequencing (NGS). 457
In order to identify those NAD-RNAs from S. aureus, we have made use of NAD captureSeq as 458 described previously (Winz et al., 2017) and applied to 100 µg total RNA from S. aureus ATCC 459 25923 per sample isolated at the late-exponential phase (OD600 = 1.5). A NAD captureSeq variant 460
was also used in order to compare the enrichment of specific RNAs between S. aureus strains 461
(pCG-P2, pCG-P3, and pCG-P3(-1G)). For that, 15 fmol of variable length (61, 104, 205, 302, 400 462 nt) NAD-RNAs were spiked into each sample, acting as internal standards (IS). The PCR products 463
were purified by polyacrylamide (PA) gel electrophoresis (PAGE), and the range between 150 and 464 300 bp selected ( Figure S1A ). This size selection helped to remove the primer dimers as well. 465
Afterwards, the quality of the samples was analysed by Bioanalyzer measurements (Bioanalyzer 466 2100, Agilent Technologies, Santa Clara, California) using the Agilent DNA 1000 Kit (Agilent). The 467
libraries were multiplexed and submitted to NGS on a NextSeq500 sequencer (Illumina, San 468
Diego, California) with the following parameters: single-end reads, 75-bp read length, read depth 469 400 million. Besides, 20% of PhiX control DNA was spiked into the samples to provide sufficient 470 read complexity. The NGS data analysis was done using an in-house pipeline. Briefly, after 471
obtaining the raw reads, the leading guanosines were trimmed, and the 3' adapter was removed 472 by clipping. Once processed, the reads were mapped to the reference genome Staphylococcus 473 aureus subsp. aureus NCTC 8325 (European Nucleotide Archive, Assembly: GCA_000013425.1) 474
and to the IS RNA sequences (in the case of the quantitative NAD captureSeq, RNA was extracted using TRIzol reagent (Thermo Fisher Scientific). Briefly, the pelleted cells were 497 resuspended in TE buffer (30 mM Tris-HCl, 1 mM EDTA, pH = 8.0) supplemented with lysozyme 498 20 mg/mL (Sigma-Aldrich, Saint Louis, Missouri) and 80 μg/mL lysostaphin (Sigma-Aldrich) and 499
incubated 30 min at 37 °C. The cells were incubated for 30 min at -80 °C before the addition of 500
the TRIzol reagent. Afterwards, the protocol proceeded according to the manufacturer's 501
instructions. Samples were treated with DNase I (1.5 U/mg total RNA, Roche, Basel, Switzerland) 502
at 37 °C for 1 hour to remove the genomic DNA, then they were P/C/I-chloroform-extracted and 503 precipitated. The RNA was washed twice with 80% ethanol and dissolved in Millipore water. The 504 quality of the RNA was assessed by agarose gel electrophoresis ( Figure S1H ). The concentration 505
and purity of the total RNA were measured by Nanodrop (Thermo Fisher Scientific), paying 506 attention to OD260/OD280 and OD260/OD230 ratios. 507
Quantitative PCR. 508
To confirm the enrichment of the obtained hits at the cDNA level and thereby rule out the 509 possible PCR bias, qPCR measurements were carried out as described before (Cahová et al., 510 2015) . 20 µL reactions were performed in triplicate using 3 µL cDNA (1:50 diluted) as a template. 511
When confirming the cDNA enrichment of the hits, APDRC-treated sample cDNA with cDNA of 512 the minus ADPRC control were compared by the 2 -ΔΔC T-method (Livak & Schmittgen, 2001 ). The 513
5SrRNA gene was used as internal control and Millipore water as a negative control. Another 514 qPCR assay was performed to check the hld/RNAIII levels of the different S. aureus strains (pCG-515 P2, pCG-P3, and pCG-P3(-1G)). 5 μg of total RNA (harvested at late-exponential phase, biological 516 triplicates) from each strain was reverse transcribed with Superscript IV reverse transcriptase 517
(Thermo Fisher Scientific) following the manufacturer's instructions. 3 µL cDNA (1:100 diluted) 518
per 20 µL reaction were used as the template. The gyrB gene was used as internal standard and 519
Millipore water as a negative control. Standard curves were determined for each gene, using 520 purified chromosomal DNA at concentrations of 0.005 to 50 ng/ml. All qPCR experiments were 521 performed in a Light Cycler 480 instrument (Roche) using the Brilliant III Ultra-Fast SYBRGreen 522
qPCR Mastermix (Agilent Technologies). The data were analyzed with the Light Cycler 480 523
Software (Agilent Technologies). The primers used for qPCR analysis are listed in Table S3 . 524
Detection of Hld by HPLC/ESI-MS. 525
The detection of Hld levels from different S. aureus strains was performed by high-performance 526 liquid chromatography/electrospray ionisation mass spectrometry (HPLC/ESI-MS) of overnight 527 culture filtrates as described earlier (Queck et al., 2008) with minor changes. The column (Zorbax 528 SBC8, 2.1 x 50 mm, 3.5 μ, Agilent Technologies) was run at 0.3 ml/min with a gradient of 0.1% 529 trifluoroacetic acid in water to 0.1% trifluoroacetic acid in acetonitrile. HPLC-MS experiments 530
were performed on a Bruker microTOFQ-II ESI mass spectrometer (Bruker, Billerica, 531
Massachussets) connected to an Agilent 1200 Series HPLC system equipped with a multi-532 wavelength detector (Agilent Technologies). ESI was used with a capillary voltage of 4,500 V, and 533 the collision voltage was set to 10 eV. The drying gas temperature was 200 °C, the drying gas flow 534 rate was 6 Lmin -1, and the detector was operated in positive ion mode. Mass spectra were 535 recorded on a range from 250 m/z to 3,000 m/z. The two m/z peaks in the mass spectrum for Hld 536
(formylated and deformylated version, Figure S1F ) were used to calculate PSM concentration by 537 integration using ACD/Spectrus software (Advanced Chemistry Development (ACD), Toronto, 538
Canada). 539
Western blotting of Hla. 540
One milliliter of cell culture filtrates from each strain (harvested at OD600 = 2.5) was filtrated and 541 concentrated (final volume 20 μL) through ultracentrifugal filters (30 kDa MWCO, Amicon, Merck, 542
Darmstadt, Germany) and analysed by 10% SDS-PAGE. After the run, SDS-PA gels were blotted 543
onto Amersham Hybond P 0.2 μm PVDF membranes (GE Healthcare, Chicago, Illinois) using an 544
EasyPhor Semi-Dry-Blotter (Biozym Scientific, Hessisch Oldendorf, Germany). Membranes were 545 blocked in TBST (Tris-buffered saline with 0.1% Tween 20) supplemented with 5% milk powder 546
(Carl Roth, Karlsruhe, Germany). Afterwards, membranes were incubated with anti-547 staphylococcal alpha-toxin rabbit antibody (1:5000, Sigma-Aldrich) in washing buffer (TBST with 548 1% milk powder). After washing, Alexa Fluor Plus 488-conjugated goat anti-rabbit IgG (Thermo 549
Fisher Scientific) in washing buffer (1:10000) was applied over the membranes. Membranes were 550
washed with 50 mM Tris-HCl, pH 7.25, and subsequently scanned using a Typhoon FLA 9500 551 imager (GE Healthcare). Quantification was done with ImageQuant TL software (GE Healthcare). 552
Detection of NAD covalently bound to RNA by UPLC/MS. 553
Samples (total RNA and pull-down RNA) were prepared as described before . 554
Briefly, RNA was extensively washed with decreasing urea concentrations in ultracentrifugal 555 filters (10 kDa MWCO, Amicon, Merck). RNA was recovered and subjected to NudC and alkaline 556 phosphatase (Sigma-Aldrich) treatment (1 h at 37 °C, 2 h for pull-down RNA) in the presence of 557 the MS internal standard (d4-riboside nicotinamide, Toronto Research Chemicals, Ontario, 558
Canada). Afterwards, the reaction mixtures were filtered through 10 kDa ultracentrifugal filters 559
(Merck) and dried under reduced pressure. Then, samples were analysed by UPLC-MS following 560 the previously described protocol . A calibration curve was recorded for r-561
NA for each analytical batch. M/z peaks of the mass spectra from the analyte and internal 562 standard were integrated with TargetLynx software (Waters corporation, Milford, 563
Massachussets). The amount of injected r-NA was calculated by integration of the corresponding 564 m/z peak using the TargetLynx software and the calibration curve. 565
Gel electrophoresis and Northern Blot analysis. 566
RNA was separated by denaturing PAGE. For NAD captureSeq NGS library generation (Qualitative 567
and Quantitative), the cDNA amplification products were purified by native PAGE. APBgels (Nübel 568 et al., 2017) were used to separate and purify NAD-RNA and ppp/p-RNA. Northern blot analysis 569 was performed as described before (Cahová et al., 2015) . RNA was separated either by PAGE or 570 PAGE-APBgels (200 V, 90 min), blotted onto a Whatman Nytran SuPerCharge nylon blotting 571 membrane (Merck) for 3 h (4 h for APBgels at 4 °C to avoid buffer evaporation) at 250 mA using 572
an EasyPhor Semi-Dry-Blotter (Biozym Scientific), and UV-crosslinked. Membranes were pre-573 hybridized in Roti-Hybri-QuickBuffer (Carl Roth) for 2 h at 48 °C. Afterward, 5 µL RNA radiolabeled 574
probe (Table S3 ) was added and incubated overnight at 48 °C in a hybridization oven with 575 rotation. The templates for the probes were prepared by PCR using Taq DNA polymerase 576
(prepared laboratory stock). Probes were prepared by in vitro transcription (IVT) in the presence 577 of 35 μCi α-32 P-ATP and 35 μCi α-32 P-CTP (3,000 Ci/mmol, each, Hartmann Analytic, 578
Braunschweig, Germany). The IVT reactions were treated with DNase I (Roche), P/C/I-579
chloroform-extracted, ethanol-precipitated and dissolved in 30 µL Millipore water. The blot was 580
washed for 30 min with wash solution 1 (2x SSC, 0.1% SDS), 30 min with wash solution 2 (1x SSC, 581 0.1% SDS) for 30 min with wash solution 3 (0.25x SSC, 0.1% SDS). Radioactive RNA was visualized 582
using storage phosphor screens (GE Healthcare) and a Typhoon FLA 9500 imager (GE Healthcare). 583
Preparation of NAD-RNAIII and ppp-RNAIII markers and IS NAD-RNAs. 584
The RNAIII markers used in the Northern blot analysis were prepared by IVT. The IVTs were 585 performed as described earlier (Huang, 2003) . Each 100 μl IVT reaction contained: 1.5-2 µg DNA 586 template and 4 mM of each NTP (6 mM NAD for NAD-RNAs; ATP concentration was reduced to 587 2 mM, or without NAD for ppp-RNAs Polymerase (NEB) and the primers listed on Table S3 . The PCR products were purified with the 596
QIAquick PCR purification kit (Qiagen, Hilden, Germany) before the IVT reactions. 597
The 5 different IS NAD-RNAs used for NAD captureSeq were also prepared by IVT (Huang, 2003) . 598
As a template, regions of E. coli's K12 genome with no homology within S. aureus genome were 599 PCR amplified (Q5 Hot Start High-Fidelity DNA Polymerase (NEB)) with the primers summarised 600
in Table S3 . The PCR products were purified with QIAquick PCR purification kit (Qiagen) before 601
IVT. IVT reactions were PAGE purified, as described above. Afterwards, the RNAs were 602 additionally purified on APBgels (5% PA, 0.4% APB) , loaded with APBgels 603 loading buffer (8 M urea, 10 mM Tris-HCl pH = 8.0, 50 mM EDTA, xylene cyanol and bromophenol) 604
and run in 1x TAE (550 V). The sequences of each IS NAD-RNA are summarised in Table S4 . 605
Preparation of radiolabeled pure NAD-RNAIII and NudC cleavage assay. 606
The radiolabeled (body labelled) pure NAD-RNAIII was prepared by IVT essentially as described 607
before (Huang, 2003) but with the presence of 100 μCi α-32 P-UTP (3,000 Ci/mmol, Hartmann 608
Analytic) per 100 μL reaction. The IVT reaction was first PAGE-purified and afterwards purified 609 on APB gels as described above to obtain 100% NAD-modified RNAIII, which was subjected to 610
NudC cleavage. The NudC cleavage assay was carried out as described before (Cahová et al., 611 2015) but with a ratio of 2 NudC:1 RNAIII. 10 μL reactions per triplicate in 1x degradation buffer 612 of full-length RNAIII, a mixture containing ~ 1:1 NAD-RNAIII and ppp-RNAIII was prepared 693
whereas the obtained NAD-RNAIII leader was 100% NAD-modified. The IVT template was 694 generated by PCR with the primers RNAIII-leader-FW and RNAIII-leader-RV. Genomic DNA from 695 S. aureus ATCC 25923 was used for the PCR. The NAD-supplemented IVT reaction was double-696 purified, first by denaturing PAGE and afterwards by APBgels, yielding NAD-RNAIII leader and 697 ppp-RNAIII leader ( Figure S1M ). 698 SHAPE was performed as described with minor modifications (Wilkinson et al., 2006) . Briefly, 8 699 pmol of RNA dissolved in 47.8 μL Millipore water were incubated for 2 min at 75 °C and then 700 cooled down to 60 °C with a ramp of 0.1 °C/s. Afterwards, 24.2 μL of Dulbecco's Phosphate 701
Buffered Saline (DPBS, Sigma-Aldrich) supplemented with 3 mM MgCl2 were added to the 702 samples, and they were incubated 2 min at 60 °C. Samples were then cooled down to 30 °C (0.1 703 °C/s) and kept 2 min at this temperature. During this step, each sample was equally divided into 704 two vials (sample vial and control vial). The vials were heated up to 37 °C, and then 4 μL of 100 705 mM 1M7 (10 mM final concentration) was added to sample vial. 1M7 was dissolved in dry DMSO 706
(Sigma-Aldrich), so the reaction control was supplemented with the same volume of dry DMSO 707 as in the sample (4 μL). The reaction mixtures were incubated for 20 min at 37 °C. Finally, 708 reactions were stopped by adding 1 reaction volume of Millipore water, and the RNA was 709 precipitated by ethanol in the presence of 0.3 M sodium acetate. The precipitated RNA was 710
washed twice with 80% ethanol and dissolved in Millipore water to a concentration of 0.5 711 pmol/mL. 712
For primer extension, 100 pmol of SHAPE-RT1 primer (Table S3 ) were radioactively labeled on its 713
5'-end with 3 µL of γ-32 P-ATP (3,000 Ci/mmol, Hartmann Analytic) per 20 μL reaction by using T4 714 polynucleotide kinase (Thermo Fisher Scientific), and further purified with the QIAquick 715
Nucleotide Removal Kit (Qiagen). Both steps were performed following the manufacturer's 716
instructions.
717
The primer extension assay was applied to the RNA samples by using Superscript IV reverse 718 transcriptase (Thermo Fisher Scientific). The reaction volume was set to 10 μL. 1 pmol of treated 719
RNA per reaction was used as a template for the reaction together with 5 μL of 5'-end 720 radiolabeled DNA primer 1 μM. A sequencing ladder was generated by reverse transcription of 1 721 pmol non-treated in vitro-transcribed ppp-RNAIII leader supplemented with 0.5 mM 722 deoxynucleotide triphosphate mix each (Sigma-Aldrich), and 1 mM of the corresponding 723 dideoxynucleotide triphosphate (Jena Bioscience, Jena, Germany). Reactions were performed 724
according to the manufacturer's instructions. The removal of residual RNA was done by addition 725 of 2 μL 1 M NaOH to the samples followed by a 5 min incubation at 90 °C. Samples were then 726
neutralised by the addition of 2 μL 1 M HCL and stored at -20 °C in denaturing gel loading buffer 727 before being analysed by PAGE. 728
Samples processed in triplicate were analysed by 15% PA sequencing gels with standard running 729 conditions (TBE buffer, 2000 V, 4h 30 min run time, Figure S1L ). Radioactive cDNA was visualised 730
with storage phosphor screens (GE Healthcare) and a Typhoon FLA 9500 imager (GE Healthcare). 731
Quantification of PA sequencing gels was done with the software SAFA (Laederach et al., 2008) . 732
The intensities of the bands were normalised, and the control lanes (DMSO treated) were 733 subtracted from the sample lanes (1M7 treated) to obtain the SHAPE values for each nucleotide. 734
The SHAPE values for each nucleotide were afterwards used in the RNAstructure software (Reuter 735 & Mathews, 2010) to create a structure prediction for the RNA sequence. 736
Statistical analysis 737
Except for NGS data analysis, where DESeq statistics was used (Anders & Huber, 2010), all 738 statistics were analysed using the software Prism 6 version 6.01 (GraphPad, San Diego, 739
California). Error bars depict standard deviations in all experiments. For specific data sets, 740
identification of outliers was performed by Grubbs' method (Alpha = 0.2). When comparing two 741 groups, the parametric unpaired two-tailed Student's t-test was selected. For the analysis of 742 experiments involving three or more groups, the parametric one-way ANOVA test was done. The 743
applied Post hoc analysis was Tukey's multiple comparisons-test. Differences were considered 744 significant when P < 0.05. Competing interests 759 760
The authors declare no competing interests. precursor peptide that is converted into an autoinducing peptide (AIP) upon proteolysis by AgrB 766 (transmembrane protein) and secreted to the exterior. The AIP then binds to the AgrC receptor, 767
triggering autophosphorylation of its intracellular histidine kinase domain. AgrA is activated by 768 the transfer of the phosphate group of AgrC and enhances transcription of P2 and P3 promoters, 769
leading to RNAII and RNAIII production. RNAII encodes all the Agr proteins (AgrB/D/C/A) whereas 770
RNAIII is a regulatory RNA also containing an ORF encoding for delta-toxin (Hld) (See text for more 771 details). pCG-P3(-1G), and pCG-P2). Highlighted are the -35 (-35, purple for P3 and light gray for P2), -10 799 (-10, brown for P3 and orange for P2) and -1 (-1, light blue for native P3, pink for mutated P3 and 800 black for native P2) regions. The first four nucleotides of RNAIII are highlighted in green.
801
B: The figure shows the workflow (steps 1 to 6) followed for the pull-down of specific RNA targets 802 and the subsequent RNA cleavage by a DNAzyme (see text for more information). 
